4//SEC Filing
ROBERTS JOHN A 4
Accession 0001493152-22-007154
CIK 0001349929other
Filed
Mar 16, 8:00 PM ET
Accepted
Mar 17, 4:15 PM ET
Size
6.1 KB
Accession
0001493152-22-007154
Insider Transaction Report
Form 4
Vyant Bio, Inc.VYNT
ROBERTS JOHN A
Chief Operating Officer
Transactions
- Award
Stock option (right to buy)
2022-03-15+150,000→ 150,000 totalExercise: $1.00Exp: 2032-03-15→ Common Stock (150,000 underlying)
Footnotes (1)
- [F1]The option shall become exercisable with respect to twenty five percent (25%) of the shares underlying the option upon the date of grant, with respect to thirty seven and a half percent (37.5)% upon the filing by the Company of an Investigational New Drug Application ("IND") with the U.S. Food and Drug Administration ("FDA") for a New Chemical Entity ("NCE") candidate to treat Rett Syndrome and with respect to the remaining thirty seven and a half percent (37.5)% upon the filing by the Company of an IND with the FDA for an NCE candidate to treat CDKL5 Deficiency Disorders; provided that the participant remains a service provider to the Company through each applicable vesting date.
Documents
Issuer
Vyant Bio, Inc.
CIK 0001349929
Entity typeother
Related Parties
1- filerCIK 0001249872
Filing Metadata
- Form type
- 4
- Filed
- Mar 16, 8:00 PM ET
- Accepted
- Mar 17, 4:15 PM ET
- Size
- 6.1 KB